<DOC>
	<DOCNO>NCT00001085</DOCNO>
	<brief_summary>To determine proportion patient whose plasma HIV-1 RNA level remain detectable level ( le 500/ml ) 24 week study therapy either 141W94 monotherapy 141W94 plus zidovudine ( ZDV ) lamivudine ( 3TC ) . To determine safety tolerability 141W94 monotherapy combination 141W94 plus 3TC patient HIV infection . Although dramatic inhibition HIV-1 replication achieve ritonavir indinavir monotherapy , case maximum suppression require combination treatment together nucleoside analog RT inhibitor . This study test hypothesis monotherapy 141W94 dos result Cmin level far excess IC90 correct plasma protein bind HIV-1 achieve virologic immunologic effect term magnitude durability , observed combination protease inhibitor plus nucleoside analog .</brief_summary>
	<brief_title>A Study 141W94 Used Alone Combination With Zidovudine Plus 3TC HIV-Infected Patients</brief_title>
	<detailed_description>Although dramatic inhibition HIV-1 replication achieve ritonavir indinavir monotherapy , case maximum suppression require combination treatment together nucleoside analog RT inhibitor . This study test hypothesis monotherapy 141W94 dos result Cmin level far excess IC90 correct plasma protein bind HIV-1 achieve virologic immunologic effect term magnitude durability , observed combination protease inhibitor plus nucleoside analog . In randomized , double-blind study , patient ' HIV RNA screen 30 day prior entry . Patients satisfy enrollment criterion must stable antiretroviral regimen 30 day prior study screen remain regimen entry . Patients stratify base screen HIV-1 RNA copy number obtain within 30 day entry : 5,000 - 50,000 copies/ml versus great 50,000 copies/ml . In addition , patient stratify base previous antiretroviral use : naive versus experience . Patients randomize one 2 treatment arm : Arm A - 141W94 , plus Zidovudine ( ZDV ) Lamivudine ( 3TC ) Arm B - 141W94 , plus ZDV placebo 3TC placebo . [ AS PER AMENDMENT 8/25/97 : Patients assign monotherapy arm advise discontinue study medication immediately initiate antiretroviral therapy indinavir , nevirapine , stavudine 3TC , outline ACTG 347 roll-over protocol , ACTG 373 . Patients three-drug arm continue study therapy . ] [ AS PER AMENDMENT 12/19/97 : Patients receive study treatment 56 week follow week 68 . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia require patient CD4 cell count &lt; = 200 cells/mm3 . Topical and/or oral antifungal agent , except list excluded medication . Treatment , maintenance chemoprophylaxis approve agent opportunistic infection clinically indicate , unless list excluded medication . All antibiotic clinically indicate . Systemic corticosteroid use &lt; = 21 day acute problem permit medically indicate ; chronic systemic corticosteroid use permit . Recombinant erythropoietin granulocyte colonystimulating factor medically indicate . Regularly prescribed medication : antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive ( barrier method also require study ) , megestrol acetate , testosterone medication , medically indicate . Alternative therapy vitamin , acupuncture visualization technique permit ( exclude herbal medication ) . NOTE : Patients report use therapy ; alternative therapy record . Patients must : HIV1 infection document ELISA confirm . &gt; = 5,000 HIV1 RNA copies/ml ( within 30 day prior study entry ) . CD4 cell count &gt; = 50 cells/mm3 within 60 day prior study entry . Signed , informed consent patient &lt; 18 year age . Prior Medication : Required : Patients must stable antiretroviral regimen 30 day prior study screen remain regimen entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Any active infection require acute treatment within 14 day prior entry . A malignancy require systemic therapy minimal Kaposi 's sarcoma . NOTE : Patients minimal Kaposi 's sarcoma , define &lt; = 5 cutaneous lesion visceral disease tumorassociated edema , allow enroll long require systemic therapy Kaposi 's sarcoma . Patients follow prior symptom condition exclude : Inability tolerate ZDV 500600 mg daily ZDV administer previously . Intolerance ZDV define grade toxicity result dose reduction termination ZDV . Prior Medication : Excluded : Any 3TC therapy prior entry . Any HIV1 protease inhibitor therapy prior study entry ( e.g. , saquinavir , ritonavir , indinavir , nelfinavir , 141W94 ) . Any immunomodulator therapy within 30 day prior entry . Active immunization within 30 day prior entry . Any antiretroviral therapy change within 30 day prior study screen . 1 . Concurrent use nonprotocol specify antiretroviral agent ; either investigational license . Immunomodulators affect immunologic virologic index systemic corticosteroid , thalidomide , cytokine . Concomitant use rifabutin and/or rifampin . Investigational drug 141W94/VX478 . Systemic cytotoxic chemotherapy . Oral astemizole ( Hismanal ) , carbamazepine ( Tegretol ) , dexamethasone ( Decadron ) , ketoconazole ( Nizoral ) , itraconazole ( Sporanox ) , phenobarbital , phenytoin ( Dilantin ) , terfenadine ( Seldane ) , cisapride ( Propulsid ) , triazolam ( Halcion ) midazolam ( Versed ) . Herbal medication .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>